Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Revista Medica De Chile|February 14, 2014
[KRAS gene mutation in colorectal cancer]Iván Roa, Tamara Sánchez, Alejandro Majlis, et al.Gynecologic Oncology|March 26, 2005
Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervixFernando Heredia, Marco Bravo, Mateo Pierotic, et al.Hematology, Transfusion and Cell Therapy|September 18, 2025
Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in the public Chilean national health system: A single center studyBarbara Puga, Francisca Bass, Javiera Molina, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinomaJaffer A Ajani, Miguel B Fodor, Sergei A Tjulandin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study GroupJaffer A Ajani, Vladimir M Moiseyenko, Sergei Tjulandin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study GroupJaffer A Ajani, Vladimir M Moiseyenko, Sergei Tjulandin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupEric Van Cutsem, Vladimir M Moiseyenko, Sergei Tjulandin, et al.Blood|May 2, 2023
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, et al.Journal of Personalized Medicine|February 25, 2022
Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean ExperienceMiguel Cordova-Delgado, Mauricio P Pinto, Carlos Regonesi, et al.Nephrology (Carlton, Vic.)|December 12, 2019
Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance-related lesions in Latin AmericaCamila Peña, Natalia P Schutz, Eloísa Riva, et al.Pageof 1